Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYND1 antisense oligonucleotides
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MYND1 antisense oligonucleotides are preclinical-stage antisense oligonucleotides (ASOs) designed to target and knock down MYND1, a novel plasma cell-specific long non-coding RNA (lncRNA). Developed by researchers at the Dana-Farber Cancer Institute and the Candiolo Cancer Institute, MYND1 is highly expressed in multiple myeloma (MM) cells and normal plasma cells but is absent or significantly lower in most other normal tissues. MYND1 shares sequence homology with U1 small nuclear RNA and interacts with key spliceosome components (such as HNRNPC, HNRNPH2, and HNRNPH3) to support splicing activity. Knockdown of MYND1 using these ASOs inhibits spliceosome-related gene signatures and significantly reduces multiple myeloma cell viability in vitro, representing a potential therapeutic strategy for multiple myeloma.
- Other names
- MYND1 ASOsMYND-1 ASOsMYND 1 ASOs
02
Targets
C2 (Complement component 2)MYND1 (MYND1 long non-coding RNA)HNRNPH2 (Heterogeneous nuclear ribonucleoprotein H2)
Beyond the preview
Go deeper on MYND1 antisense oligonucleotides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYND1 antisense oligonucleotides.